Hanmi Pharm announced the three study results of LAPSTriple Agonist, which is being developed by the company as a first-in-class nonalcoholic steatohepatitis (NASH) treatment, at the American Association for the Study of Liver Diseases (AASLD).
In August, Hanmi Pharm also released clinical and full-time data of the LAPSTriple Agonist at the EASL (The European Association for the Study of the Liver)’s International Liver Congress (ILC), which will be attended by experts from across Europe.
LAPSTriple Agonist is a candidate for a triple-acting bio-pharmaceutical drug that simultaneously activates glucagon, which increases the body's energy metabolism, GLP-1 that helps insulin secretion and curbs appetite, and anti-inflammatory GIP receptors.
Through analysis of various animal model tissues, Hanmi Pharm announced that LAPSTriple Agonist has a therapeutic effect on NASH, which is a combination of fat, hepatitis and liver fibrosis in the liver.
As Hanmi Pharm also proved the clear improvement of LAPSTriple Agonist in fatty liver patients at the EASL in August, the company plans to accelerate its development as a "first-in-class" NASH treatment in the NASH sector, which currently has no treatment.
LAPSTriple Agonist was designated as a fast track by the U.S. FDA in July, and is currently undergoing Phase 2 clinical trials in the U.S. to validate therapeutic efficacy for NASH patients whose diseases have been confirmed by biopsy.
In addition, it was designated as a rare drug by the FDA in March to treat the rare diseases such as primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC).
"LAPSTriple Agonist is an innovative new drug that simultaneously targets various NASH symptoms. We will do our best to commercialize it as soon as possible as experts from the world's largest academic societies in the U.S. and Europe are paying attention to it," said Kwon Se-chang, CEO of Hanmi Pharm.
